Drugs.com - Clinical Trials

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

RAHWAY, N.J.--(BUSINESS WIRE) June 9, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of...

Jun 10, 2025 - 03:00
 0
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
RAHWAY, N.J.--(BUSINESS WIRE) June 9, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of...
Read More

Tags:

Previous Article

Rejoignez L'Oréal, LVMH, Prose et d'autres leaders pour une journée d'innovation

Next Article

FDA Approves Widaplik (telmisartan, amlodipine and indapamide) for the Treatment...

Related Posts

Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer

Pheast Therapeutics Receives FDA Fast Track Designation...

Jun 3, 2025  0

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST - Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen Announces Rare Pediatric Disease Designation Gra...

May 30, 2025  0

GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus in Primary Biliary Cholangitis

GLISTEN Phase III Trial Results Show Linerixibat Signif...

May 12, 2025  0